Sanofi SA's Fiscal Year is From January To December - All Figures are in EUR, Billions.
The item "Net-Income-From-Continuing-Operations" stands at 6.23 Billion Euros for the trailing twelve months (TTM) period ending 09/30/2025.
Sanofi SA's third quarter result of 2.83 Billion EUR for the item "Net Income From Continuing Operations" represents an increase of 128.62 percent compared to it's second quarter result.
Also, Sanofi SA's third quarter result of 2.83 Billion EUR for the item "Net Income From Continuing Operations" represents a decrease of -0.56 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Sanofi SA's third quarter result of 6.23 Billion EUR for the item "Net Income From Continuing Operations" represents a decrease of -0.26 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 36.98 percent compared to the value the year prior.
The 1 year change in percent is 36.98.
The 3 year change in percent is -3.50.
The 5 year change in percent is -32.99.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Net Income From Continuing Operations | 905,699,262,464.00 |
![]() | Johnson & Johnson - Net Income From Continuing Operations | 486,508,953,600.00 |
![]() | AbbVie Inc - Net Income From Continuing Operations | 399,570,305,024.00 |
![]() | Roche Holding AG - Net Income From Continuing Operations | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Net Income From Continuing Operations | 280,205,508,085.11 |